Safety and tolerability of Bifidobacterium longum subspecies infantis EVC001 supplementation in healthy term breastfed infants: a phase I clinical trial

Abstract

BackgroundHistorically, bifidobacteria were the dominant intestinal bacteria in breastfed infants. Still abundant in infants in developing nations, levels of intestinal bifidobacteria are low among infants in developed nations. Recent studies have described an intimate relationship between human milk and a specific subspecies of Bifidobacterium, B. longum subsp. infantis (B. infantis), yet supplementation of breastfed, healthy, term infants with this organism, has not been reported. The IMPRINT Study, a Phase I clinical trial, was initiated to determine the safety and tolerability of supplementing breastfed infants with B. infantis (EVC001).MethodsEighty mother-infant dyads were enrolled in either lactation support plus B. infantis supplementation (BiLS) or lactation support alone (LS). Starting with Day 7 postnatal, BiLS infants were fed 1.8–2.8 × 1010 CFU B. infantis EVC001 daily in breast milk for 21 days. Mothers collected fecal samples, filled out health questionnaires, and kept daily logs about their infants’ feeding and gastrointestinal symptoms from birth until Day 61 postnatal. Safety and tolerability were determined from maternal reports.ResultsThere were no differences in the mean gestational age at birth, weight 1 and 2 months postnatal, and breast milk intake between groups. The mean Log10 change in fecal Bifidobacterium from Day 6 to Day 28 was higher (p = 0.0002) for BiLS (6.6 ± 2.8 SD) than for LS infants (3.5 ± 3.5 SD). Daily stool number was higher (p < 0.005) for LS and lower (p < 0.05) for BiLS infants during supplementation than at Baseline. During supplementation, watery stools decreased and soft stools increased by 36% over baseline in BiLS infants (p < 0.05) with no significant changes in stool consistency for the LS infants. None of the safety and tolerability endpoints, including flatulence, bloody stool, body temperature, ratings of gastrointestinal symptoms, use of antibiotics or gas-relieving medications, infant colic, jaundice, number of illnesses, sick doctor visits, or diagnoses of eczema were different for the groups at any point.ConclusionsThe B. infantis EVC001 supplement was safely consumed and well-tolerated. Stools were fewer and better formed in infants in the BiLS group compared with LS group. Adverse events were those expected in healthy infants and not different between groups.Trial registrationClinicalTrials.gov NCT02457338. Registered May 27, 2015.Electronic supplementary materialThe online version of this article (doi:10.1186/s12887-017-0886-9) contains supplementary material, which is available to authorized users.

Parturition and the perinatal period: can mode of delivery impact on the future health of the neonate?

“…Supplementation significantly increased the level of B. infantis in infant faecal samples compared to the control (Smilowitz et al . ), an effect that persisted for more than 30 days after supplementation. B. infantis supplementation also led to an increase in faecal acetate and lactate, decreases in faecal pH and bacterial endotoxin and fewer stools, all indications of improved microbiome (Frese et al .…”

Modulation of Type 1 Diabetes Risk by the Intestinal Microbiome

“…This observation was largely driven by the Finnish participants with the highest frequency of probiotic use but on the other hand the highest T1D incidence. The Bifidobacterium longum infantis subspecies has been shown to colonize effectively the intestinal tract in breast-fed infants when given during the first 4 weeks after birth [47]. This bacteria is highly abundant as long as the mother is breast-feeding, which prevents colonization with pathogenic bacteria.…”

Colonization Resistance in the Infant Gut: The Role of B. infantis in Reducing pH and Preventing Pathogen Growth

“…Interestingly, changes in infant stool pH appeared to have occurred predominantly in industrialized regions such as the United States and Europe [5]. Conversely, in less-industrialized nations, where breastfeeding rates remain high and microbiome-modifying interventions are less common (e.g., limited exposure to antibiotics and c-section births), Bifidobacterium dominates the microbiome of infants [6,7].…”